Galimedix, Inc. | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128173	Articles
104823	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 1 month ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy
BRIEF

published on 12/05/2024 at 13:33, 1 year 2 months ago

Galimedix Therapeutics lance une étude de phase 1 avec le GAL-101 oral

Étude De Phase 1 La Maladie D'Alzheimer GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 12/05/2024 at 13:33, 1 year 2 months ago

Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Dry AMD Phase 1 Study
PRESS RELEASE

published on 12/05/2024 at 13:28, 1 year 2 months ago

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments

Galimedix Therapeutics Neurodegenerative Diseases GAL-101 Alzheimer's Phase 1 Study
BRIEF

published on 06/10/2024 at 14:05, 1 year 7 months ago

Galimedix Therapeutics réunit son conseil consultatif scientifique pour l'étude de phase 2 du GAL-101

Étude Clinique De Phase 2 Conseil Consultatif Scientifique GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 06/10/2024 at 14:05, 1 year 7 months ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
PRESS RELEASE

published on 06/10/2024 at 14:00, 1 year 7 months ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts
BRIEF

published on 03/08/2024 at 10:05, 1 year 11 months ago

Galimedix Therapeutics dévoile des données prometteuses sur le traitement de la maladie d'Alzheimer à l'occasion de l'AD/PD™ 2024

Développement Clinique GAL-201 La Maladie D'Alzheimer Effets Neuroprotecteurs Fonction Cognitive
BRIEF

published on 03/08/2024 at 10:05, 1 year 11 months ago

Galimedix Therapeutics Unveils Promising Data on Alzheimer’s Treatment at AD/PD™ 2024

Clinical Development GAL-201 Alzheimer’s Disease Neuroprotective Effects Cognitive Function
PRESS RELEASE

published on 03/08/2024 at 10:00, 1 year 11 months ago

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics presents new scientific data at AD/PD(TM) 2024, showing neuroprotective effects of GAL-201 for Alzheimer’s disease treatment, targeting misfolded Aβ monomers to prevent toxic aggregation

Alzheimer's Disease Galimedix Therapeutics Neuroprotective Effects Scientific Data AD/PD 2024

Accesswire

Published on 02/08/2026 at 21:00, 7 hours 19 minutes ago

Banyan Gold Extends Airstrip and High-Grade Mineralization to 350m Vertical Depth, Yukon, Canada
Published on 02/07/2026 at 01:00, 2 days 3 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 2 days 5 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 2 days 6 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 2 days 12 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 1 day 7 hours ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 1 day 11 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 1 day 11 hours ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 2 days 8 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 2 days 10 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 2 days 9 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 2 days 9 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 2 days 12 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 2 days 12 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 20 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE